• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Novel Onset of Cutaneous Lupus Erythematosus Induced by Pembrolizumab.

作者信息

Pogorelov Dimitrii, Strotkötter Heribert, Bjelic-Radisic Vesna, Wesselmann Ulrich, Hübinger Jonas, Sabulyte Simona, Hofmann Silke C, Balakirski Galina

机构信息

Center for Dermatology, Allergology und Dermatosurgery, Helios University Hospital Wuppertal, University Witten/Herdecke, Wuppertal, Germany.

Medical Care Centre for Outpatient Radiotherapy, Nuclear Medicine and Oncology, Helios Wuppertal, Wuppertal, Germany.

出版信息

Acta Derm Venereol. 2024 Sep 30;104:adv40801. doi: 10.2340/actadv.v104.40801.

DOI:10.2340/actadv.v104.40801
PMID:39347691
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11458919/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32d7/11458919/7afa4d2a26a7/ActaDV-104-40801-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32d7/11458919/0bb9adcfa110/ActaDV-104-40801-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32d7/11458919/92384a9895bc/ActaDV-104-40801-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32d7/11458919/7afa4d2a26a7/ActaDV-104-40801-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32d7/11458919/0bb9adcfa110/ActaDV-104-40801-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32d7/11458919/92384a9895bc/ActaDV-104-40801-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32d7/11458919/7afa4d2a26a7/ActaDV-104-40801-g003.jpg

相似文献

1
Novel Onset of Cutaneous Lupus Erythematosus Induced by Pembrolizumab.帕博利珠单抗诱发的新型皮肤红斑狼疮发病
Acta Derm Venereol. 2024 Sep 30;104:adv40801. doi: 10.2340/actadv.v104.40801.
2
Late onset of subacute cutaneous lupus erythematosus following pembrolizumab therapy.帕博利珠单抗治疗后迟发性亚急性皮肤型红斑狼疮
Eur J Cancer. 2021 Mar;145:168-170. doi: 10.1016/j.ejca.2020.12.017. Epub 2021 Jan 21.
3
Onset of subacute cutaneous lupus erythematosus after the initiation of immune checkpoint inhibitor therapy of cancer.癌症免疫检查点抑制剂治疗开始后出现亚急性皮肤型红斑狼疮。
Lupus. 2021 Mar;30(3):531-533. doi: 10.1177/0961203320983448. Epub 2021 Jan 6.
4
Pembrolizumab- induced subacute cutaneous lupus erythematosus in a patient with oropharyngeal squamous cell carcinoma: A case report and literature review.帕博利珠单抗诱导的口咽鳞状细胞癌患者亚急性皮肤型红斑狼疮：一例报告及文献综述
Hum Vaccin Immunother. 2025 Dec;21(1):2454073. doi: 10.1080/21645515.2025.2454073. Epub 2025 Jan 21.
5
Subacute cutaneous lupus erythematosus with melanocyte elimination induced by pembrolizumab.帕博利珠单抗诱导的伴有黑素细胞清除的亚急性皮肤型红斑狼疮。
J Dermatol. 2020 Jun;47(6):e217-e219. doi: 10.1111/1346-8138.15316. Epub 2020 Mar 15.
6
Chilblain lupus-like cutaneous reaction associated with systemic lupus erythematosus induced by immune checkpoint inhibitor.免疫检查点抑制剂诱发的与系统性红斑狼疮相关的冻疮样狼疮样皮肤反应。
Rheumatology (Oxford). 2021 Dec 24;61(1):e13-e14. doi: 10.1093/rheumatology/keab670.
7
Cutaneous lupus associated with pembrolizumab therapy for advanced melanoma: a report of three cases.帕博利珠单抗治疗晚期黑色素瘤相关皮肤狼疮：三例报告。
Melanoma Res. 2019 Jun;29(3):338-341. doi: 10.1097/CMR.0000000000000587.
8
Clinical characteristics, treatment and outcome of subacute cutaneous lupus erythematosus induced by PD-1/PD-L1 inhibitors.由 PD-1/PD-L1 抑制剂引起的亚急性皮肤型狼疮的临床特征、治疗和转归。
Arch Dermatol Res. 2024 Oct 26;316(10):722. doi: 10.1007/s00403-024-03484-1.
9
Case Report: Subacute cutaneous lupus erythematosus induced by the anti-PD-1 antibody camrelizumab combined with chemotherapy.病例报告：抗程序性死亡蛋白1（PD-1）抗体卡瑞利珠单抗联合化疗诱发亚急性皮肤型红斑狼疮
Front Immunol. 2025 Mar 28;16:1539373. doi: 10.3389/fimmu.2025.1539373. eCollection 2025.
10
Drug-induced subacute cutaneous lupus erythematosus associated with abatacept.与阿巴西普相关的药物性亚急性皮肤型红斑狼疮
Lupus. 2021 Apr;30(4):661-663. doi: 10.1177/0961203320981146. Epub 2020 Dec 22.

引用本文的文献

1
[New-onset nail psoriasis after treatment with pembrolizumab and durvalumab].[帕博利珠单抗和度伐利尤单抗治疗后新发甲银屑病]
Dermatologie (Heidelb). 2025 May;76(5):300. doi: 10.1007/s00105-025-05496-y. Epub 2025 Apr 1.

本文引用的文献

1
Immune checkpoint inhibitor-induced subacute cutaneous lupus erythematosus: a case report and review of the literature.免疫检查点抑制剂诱发的亚急性皮肤型红斑狼疮：一例报告并文献复习
Front Med (Lausanne). 2024 Feb 1;11:1334718. doi: 10.3389/fmed.2024.1334718. eCollection 2024.
2
Incidence and risk factors of immune-related adverse events induced by immune checkpoint inhibitors among older adults with non-small cell lung cancer.免疫检查点抑制剂在老年非小细胞肺癌患者中引起的免疫相关不良事件的发生率和危险因素。
Cancer Med. 2024 Jan;13(1):e6879. doi: 10.1002/cam4.6879. Epub 2024 Jan 2.
3
Manifestation of subacute cutaneous lupus erythematosus during treatment with anti-PD-1 antibody cemiplimab - a case report.
抗程序性死亡蛋白1（PD-1）抗体西米普利单抗治疗期间亚急性皮肤型红斑狼疮的表现——病例报告
Front Immunol. 2023 Dec 8;14:1324231. doi: 10.3389/fimmu.2023.1324231. eCollection 2023.
4
Nivolumab-Induced de novo Discoid Lupus Erythematosus.纳武单抗诱发的新发盘状红斑狼疮
Case Rep Dermatol. 2022 Apr 21;14(1):88-92. doi: 10.1159/000523800. eCollection 2022 Jan-Apr.
5
Adverse cutaneous toxicities by PD-1/PD-L1 immune checkpoint inhibitors: pathogenesis, treatment, and surveillance.PD-1/PD-L1 免疫检查点抑制剂的皮肤毒性不良反应：发病机制、治疗和监测。
Cutan Ocul Toxicol. 2022 Mar;41(1):73-90. doi: 10.1080/15569527.2022.2034842. Epub 2022 Feb 20.
6
Late onset of subacute cutaneous lupus erythematosus following pembrolizumab therapy.帕博利珠单抗治疗后迟发性亚急性皮肤型红斑狼疮
Eur J Cancer. 2021 Mar;145:168-170. doi: 10.1016/j.ejca.2020.12.017. Epub 2021 Jan 21.
7
Subacute cutaneous lupus erythematosus induced by PD-1 Inhibitor therapy: two case reports and literature review.PD-1抑制剂治疗诱发的亚急性皮肤型红斑狼疮：两例病例报告及文献综述
Australas J Dermatol. 2021 May;62(2):e347-e349. doi: 10.1111/ajd.13538. Epub 2021 Jan 23.
8
Onset of subacute cutaneous lupus erythematosus after the initiation of immune checkpoint inhibitor therapy of cancer.癌症免疫检查点抑制剂治疗开始后出现亚急性皮肤型红斑狼疮。
Lupus. 2021 Mar;30(3):531-533. doi: 10.1177/0961203320983448. Epub 2021 Jan 6.
9
Systematic Review: Monoclonal Antibody-Induced Subacute Cutaneous Lupus Erythematosus.系统评价：单克隆抗体诱导的亚急性皮肤型红斑狼疮。
Drugs R D. 2020 Dec;20(4):319-330. doi: 10.1007/s40268-020-00320-5.
10
De novo subacute cutaneous lupus erythematosus-like eruptions in the setting of programmed death-1 or programmed death ligand-1 inhibitor therapy: clinicopathological correlation.程序性死亡受体-1 或程序性死亡配体-1 抑制剂治疗中出现新发亚急性皮肤狼疮样疹：临床病理相关性。
Clin Exp Dermatol. 2021 Mar;46(2):328-337. doi: 10.1111/ced.14449. Epub 2020 Oct 14.